Opioid Induced Constipation (OIC) Drug Market Report

Japan Opioid Induced Constipation (OIC) Drug Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Dec 20, 2019
  • PAGES：184
  • REPORT CODE：GMM405210
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan Opioid Induced Constipation (OIC) Drug market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan Opioid Induced Constipation (OIC) Drug market. Detailed analysis of key players, along with key growth strategies adopted by Opioid Induced Constipation (OIC) Drug industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Progenics Pharmaceuticals

    • Allergan

    • Ironwood Pharmaceuticals

    • Cosmo Pharmaceuticals SA

    • Daewoong Pharmaceutical

    • Shionogi &

    • Theravance Biopharma

    • Ono Pharmaceutical

    • Nektar Therapeutics

    • Valeant Pharmaceuticals International

    • Daiichi Sankyo Co

    • Takeda Pharmaceutical Company Limited

    • Pfizer

    • Sucampo Pharmaceuticals

    • Purdue Pharma

    • Mundipharma International Limited

    By Type:

    • Lubiprostone

    • Methyl Naltrexone Bromide

    • Naldemedine

    • Alvimopan

    • Other

    By End-User:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Opioid Induced Constipation (OIC) Drug Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Lubiprostone from 2014 to 2026

      • 1.3.2 Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Methyl Naltrexone Bromide from 2014 to 2026

      • 1.3.3 Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Naldemedine from 2014 to 2026

      • 1.3.4 Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Alvimopan from 2014 to 2026

      • 1.3.5 Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Other from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

      • 1.4.2 Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

      • 1.4.3 Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Opioid Induced Constipation (OIC) Drug Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Opioid Induced Constipation (OIC) Drug by Major Types

      • 3.4.1 Market Size and Growth Rate of Lubiprostone

      • 3.4.2 Market Size and Growth Rate of Methyl Naltrexone Bromide

      • 3.4.3 Market Size and Growth Rate of Naldemedine

      • 3.4.4 Market Size and Growth Rate of Alvimopan

      • 3.4.5 Market Size and Growth Rate of Other

    4 Segmentation of Opioid Induced Constipation (OIC) Drug Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Opioid Induced Constipation (OIC) Drug by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Opioid Induced Constipation (OIC) Drug in Hospital Pharmacies

      • 4.4.2 Market Size and Growth Rate of Opioid Induced Constipation (OIC) Drug in Retail Pharmacies

      • 4.4.3 Market Size and Growth Rate of Opioid Induced Constipation (OIC) Drug in Online Pharmacies

    5 Market Analysis by Regions

    • 5.1 Japan Opioid Induced Constipation (OIC) Drug Production Analysis by Regions

    • 5.2 Japan Opioid Induced Constipation (OIC) Drug Consumption Analysis by Regions

    6 Hokkaido Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 6.1 Hokkaido Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 6.2 Hokkaido Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    7 Tohoku Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 7.1 Tohoku Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 7.2 Tohoku Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    8 Kanto Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 8.1 Kanto Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 8.2 Kanto Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    9 Chubu Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 9.1 Chubu Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 9.2 Chubu Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    10 Kinki Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 10.1 Kinki Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 10.2 Kinki Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    11 Chugoku Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 11.1 Chugoku Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 11.2 Chugoku Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    12 Shikoku Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 12.1 Shikoku Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 12.2 Shikoku Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    13 Kyushu Opioid Induced Constipation (OIC) Drug Landscape Analysis

    • 13.1 Kyushu Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major Types

    • 13.2 Kyushu Opioid Induced Constipation (OIC) Drug Landscape Analysis by Major End-Users

    14 Major Players Profiles

    • 14.1 Progenics Pharmaceuticals

      • 14.1.1 Progenics Pharmaceuticals Company Profile and Recent Development

      • 14.1.2 Market Performance

      • 14.1.3 Product and Service Introduction

    • 14.2 Allergan

      • 14.2.1 Allergan Company Profile and Recent Development

      • 14.2.2 Market Performance

      • 14.2.3 Product and Service Introduction

    • 14.3 Ironwood Pharmaceuticals

      • 14.3.1 Ironwood Pharmaceuticals Company Profile and Recent Development

      • 14.3.2 Market Performance

      • 14.3.3 Product and Service Introduction

    • 14.4 Cosmo Pharmaceuticals SA

      • 14.4.1 Cosmo Pharmaceuticals SA Company Profile and Recent Development

      • 14.4.2 Market Performance

      • 14.4.3 Product and Service Introduction

    • 14.5 Daewoong Pharmaceutical

      • 14.5.1 Daewoong Pharmaceutical Company Profile and Recent Development

      • 14.5.2 Market Performance

      • 14.5.3 Product and Service Introduction

    • 14.6 Shionogi &

      • 14.6.1 Shionogi & Company Profile and Recent Development

      • 14.6.2 Market Performance

      • 14.6.3 Product and Service Introduction

    • 14.7 Theravance Biopharma

      • 14.7.1 Theravance Biopharma Company Profile and Recent Development

      • 14.7.2 Market Performance

      • 14.7.3 Product and Service Introduction

    • 14.8 Ono Pharmaceutical

      • 14.8.1 Ono Pharmaceutical Company Profile and Recent Development

      • 14.8.2 Market Performance

      • 14.8.3 Product and Service Introduction

    • 14.9 Nektar Therapeutics

      • 14.9.1 Nektar Therapeutics Company Profile and Recent Development

      • 14.9.2 Market Performance

      • 14.9.3 Product and Service Introduction

    • 14.10 Valeant Pharmaceuticals International

      • 14.10.1 Valeant Pharmaceuticals International Company Profile and Recent Development

      • 14.10.2 Market Performance

      • 14.10.3 Product and Service Introduction

    • 14.11 Daiichi Sankyo Co

      • 14.11.1 Daiichi Sankyo Co Company Profile and Recent Development

      • 14.11.2 Market Performance

      • 14.11.3 Product and Service Introduction

    • 14.12 Takeda Pharmaceutical Company Limited

      • 14.12.1 Takeda Pharmaceutical Company Limited Company Profile and Recent Development

      • 14.12.2 Market Performance

      • 14.12.3 Product and Service Introduction

    • 14.13 Pfizer

      • 14.13.1 Pfizer Company Profile and Recent Development

      • 14.13.2 Market Performance

      • 14.13.3 Product and Service Introduction

    • 14.14 Sucampo Pharmaceuticals

      • 14.14.1 Sucampo Pharmaceuticals Company Profile and Recent Development

      • 14.14.2 Market Performance

      • 14.14.3 Product and Service Introduction

    • 14.15 Purdue Pharma

      • 14.15.1 Purdue Pharma Company Profile and Recent Development

      • 14.15.2 Market Performance

      • 14.15.3 Product and Service Introduction

    • 14.16 Mundipharma International Limited

      • 14.16.1 Mundipharma International Limited Company Profile and Recent Development

      • 14.16.2 Market Performance

      • 14.16.3 Product and Service Introduction

     

    The List of Tables and Figures (Totals 90 Figures and 170 Tables)

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Lubiprostone from 2014 to 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Methyl Naltrexone Bromide from 2014 to 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Naldemedine from 2014 to 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Alvimopan from 2014 to 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Other from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu Opioid Induced Constipation (OIC) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Opioid Induced Constipation (OIC) Drug Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Opioid Induced Constipation (OIC) Drug

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Opioid Induced Constipation (OIC) Drug by Different Types from 2014 to 2026

    • Table Consumption Share of Opioid Induced Constipation (OIC) Drug by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Lubiprostone

    • Figure Market Size and Growth Rate of Methyl Naltrexone Bromide

    • Figure Market Size and Growth Rate of Naldemedine

    • Figure Market Size and Growth Rate of Alvimopan

    • Figure Market Size and Growth Rate of Other

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Opioid Induced Constipation (OIC) Drug by Different End-Users from 2014 to 2026

    • Table Consumption Share of Opioid Induced Constipation (OIC) Drug by Different End-Users from 2014 to 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure Japan Opioid Induced Constipation (OIC) Drug Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • Table Japan Opioid Induced Constipation (OIC) Drug Production by Regions

    • Table Japan Opioid Induced Constipation (OIC) Drug Production Share by Regions

    • Figure Japan Opioid Induced Constipation (OIC) Drug Production Share by Regions in 2014

    • Figure Japan Opioid Induced Constipation (OIC) Drug Production Share by Regions in 2018

    • Figure Japan Opioid Induced Constipation (OIC) Drug Production Share by Regions in 2026

    • Table Japan Opioid Induced Constipation (OIC) Drug Consumption by Regions

    • Table Japan Opioid Induced Constipation (OIC) Drug Consumption Share by Regions

    • Figure Japan Opioid Induced Constipation (OIC) Drug Consumption Share by Regions in 2014

    • Figure Japan Opioid Induced Constipation (OIC) Drug Consumption Share by Regions in 2018

    • Figure Japan Opioid Induced Constipation (OIC) Drug Consumption Share by Regions in 2026

    • Table Hokkaido Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2014

    • Figure Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2018

    • Figure Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2026

    • Table Hokkaido Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2014

    • Figure Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2018

    • Figure Hokkaido Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2026

    • Table Tohoku Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Tohoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Figure Tohoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2014

    • Figure Tohoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2018

    • Figure Tohoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2026

    • Table Tohoku Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Tohoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2014

    • Figure Tohoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2018

    • Figure Tohoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2026

    • Table Kanto Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Kanto Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Figure Kanto Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2014

    • Figure Kanto Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2018

    • Figure Kanto Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2026

    • Table Kanto Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Kanto Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2014

    • Figure Kanto Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2018

    • Figure Kanto Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2026

    • Table Chubu Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Chubu Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Figure Chubu Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2014

    • Figure Chubu Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2018

    • Figure Chubu Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2026

    • Table Chubu Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Chubu Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2014

    • Figure Chubu Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2018

    • Figure Chubu Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2026

    • Table Kinki Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Kinki Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Figure Kinki Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2014

    • Figure Kinki Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2018

    • Figure Kinki Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2026

    • Table Kinki Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Kinki Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2014

    • Figure Kinki Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2018

    • Figure Kinki Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2026

    • Table Chugoku Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Chugoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Figure Chugoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2014

    • Figure Chugoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2018

    • Figure Chugoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2026

    • Table Chugoku Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Chugoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2014

    • Figure Chugoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2018

    • Figure Chugoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2026

    • Table Shikoku Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Shikoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Figure Shikoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2014

    • Figure Shikoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2018

    • Figure Shikoku Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2026

    • Table Shikoku Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Shikoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2014

    • Figure Shikoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2018

    • Figure Shikoku Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2026

    • Table Kyushu Opioid Induced Constipation (OIC) Drug Consumption by Types from 2014 to 2026

    • Table Kyushu Opioid Induced Constipation (OIC) Drug Consumption Share by Types from 2014 to 2026

    • Figure Kyushu Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2014

    • Figure Kyushu Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2018

    • Figure Kyushu Opioid Induced Constipation (OIC) Drug Consumption Share by Types in 2026

    • Table Kyushu Opioid Induced Constipation (OIC) Drug Consumption by End-Users from 2014 to 2026

    • Table Kyushu Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2014

    • Figure Kyushu Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2018

    • Figure Kyushu Opioid Induced Constipation (OIC) Drug Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of Progenics Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Progenics Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Progenics Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Progenics Pharmaceuticals

    • Table Product and Service Introduction of Progenics Pharmaceuticals

    • Table Company Profile and Development Status of Allergan

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Allergan

    • Figure Sales and Growth Rate Analysis of Allergan

    • Figure Revenue and Market Share Analysis of Allergan

    • Table Product and Service Introduction of Allergan

    • Table Company Profile and Development Status of Ironwood Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ironwood Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Ironwood Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Ironwood Pharmaceuticals

    • Table Product and Service Introduction of Ironwood Pharmaceuticals

    • Table Company Profile and Development Status of Cosmo Pharmaceuticals SA

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Cosmo Pharmaceuticals SA

    • Figure Sales and Growth Rate Analysis of Cosmo Pharmaceuticals SA

    • Figure Revenue and Market Share Analysis of Cosmo Pharmaceuticals SA

    • Table Product and Service Introduction of Cosmo Pharmaceuticals SA

    • Table Company Profile and Development Status of Daewoong Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Daewoong Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Daewoong Pharmaceutical

    • Figure Revenue and Market Share Analysis of Daewoong Pharmaceutical

    • Table Product and Service Introduction of Daewoong Pharmaceutical

    • Table Company Profile and Development Status of Shionogi &

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shionogi &

    • Figure Sales and Growth Rate Analysis of Shionogi &

    • Figure Revenue and Market Share Analysis of Shionogi &

    • Table Product and Service Introduction of Shionogi &

    • Table Company Profile and Development Status of Theravance Biopharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Theravance Biopharma

    • Figure Sales and Growth Rate Analysis of Theravance Biopharma

    • Figure Revenue and Market Share Analysis of Theravance Biopharma

    • Table Product and Service Introduction of Theravance Biopharma

    • Table Company Profile and Development Status of Ono Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ono Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Ono Pharmaceutical

    • Figure Revenue and Market Share Analysis of Ono Pharmaceutical

    • Table Product and Service Introduction of Ono Pharmaceutical

    • Table Company Profile and Development Status of Nektar Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nektar Therapeutics

    • Figure Sales and Growth Rate Analysis of Nektar Therapeutics

    • Figure Revenue and Market Share Analysis of Nektar Therapeutics

    • Table Product and Service Introduction of Nektar Therapeutics

    • Table Company Profile and Development Status of Valeant Pharmaceuticals International

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Valeant Pharmaceuticals International

    • Figure Sales and Growth Rate Analysis of Valeant Pharmaceuticals International

    • Figure Revenue and Market Share Analysis of Valeant Pharmaceuticals International

    • Table Product and Service Introduction of Valeant Pharmaceuticals International

    • Table Company Profile and Development Status of Daiichi Sankyo Co

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Daiichi Sankyo Co

    • Figure Sales and Growth Rate Analysis of Daiichi Sankyo Co

    • Figure Revenue and Market Share Analysis of Daiichi Sankyo Co

    • Table Product and Service Introduction of Daiichi Sankyo Co

    • Table Company Profile and Development Status of Takeda Pharmaceutical Company Limited

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda Pharmaceutical Company Limited

    • Figure Sales and Growth Rate Analysis of Takeda Pharmaceutical Company Limited

    • Figure Revenue and Market Share Analysis of Takeda Pharmaceutical Company Limited

    • Table Product and Service Introduction of Takeda Pharmaceutical Company Limited

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Sucampo Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sucampo Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Sucampo Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Sucampo Pharmaceuticals

    • Table Product and Service Introduction of Sucampo Pharmaceuticals

    • Table Company Profile and Development Status of Purdue Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Purdue Pharma

    • Figure Sales and Growth Rate Analysis of Purdue Pharma

    • Figure Revenue and Market Share Analysis of Purdue Pharma

    • Table Product and Service Introduction of Purdue Pharma

    • Table Company Profile and Development Status of Mundipharma International Limited

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Mundipharma International Limited

    • Figure Sales and Growth Rate Analysis of Mundipharma International Limited

    • Figure Revenue and Market Share Analysis of Mundipharma International Limited

    • Table Product and Service Introduction of Mundipharma International Limited

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US